Abstract P2-14-05: Emerging molecular variants by circulating tumor DNA after immunotherapy in metastatic breast cancer

Anthony K. Kang(Northwestern University), Massimo Cristofanilli(Cornell University), Andrew A. Davis(Northwestern University), Ami N. Shah(Northwestern University), Michael Gurley(Northwestern University), Firas Wehbe(Northwestern University), Lorenzo Gerratana(National Cancer Institute), Paolo D’Amico(Ripamonti), Meilynn Shi(Northwestern University), Carolina Reduzzi(Cornell University), Amir Behdad(Beth Israel Deaconess Medical Center), Saya Jacob(University of Pennsylvania), Neelima Katam(Northwestern University), Jeeven Srivastava(Northwestern University), Qiang Zhang(Northwestern University), Shruti Chandra(Northwestern University)
Cancer Research
February 15, 2022
10.1158/1538-7445.sabcs21-p2-14-05
Cited by 0

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Targeting the microenvironment in solid tumors
|Cancer Treatment Reviews|2018|516
The Landscape of Targeted Therapies in TNBC
|Cancers|2020|448